Transaktioner

Healthcare

Filter

Countries

Sectors

Transaction types

    • Directed new share issue in Wilson Therapeutics AB (SE) — SEK 244 million

      Directed new share issue in Wilson Therapeutics AB (SE) — SEK 244 million

      Carnegie acted as joint bookrunner in the directed new share issue of 2,572,024 million new shares at a subscription price of SEK 95.00 per share. Wilson Therapeutics is a biopharmaceutical company that develops novel therapies for patients with rare diseases. December 2017.

    • Initial public offering  of Orphazyme (DK) on Nasdaq Copenhagen — DKK 600 million

      Initial public offering of Orphazyme (DK) on Nasdaq Copenhagen — DKK 600 million

      Carnegie acted as joint global co-ordinator and joint bookrunner in the initial public offering of Orphazyme on Nasdaq Copenhagen. Orphazyme is a Danish biotech company with a late stage orphan drug pipeline, developing new treatment options for orphan protein misfolding diseases. November 2017.

    • Initial public offering of BioArctic AB (SE) on Nasdaq Stockholm  – SEK 805 million

      Initial public offering of BioArctic AB (SE) on Nasdaq Stockholm – SEK 805 million

      Carnegie acted as sole global co-ordinator and joint bookrunner in the initial public offering of BioArctic on Nasdaq Stockholm. BioArctic develops disease-modifying treatments based on monoclonal antibodies for the treatment of neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease, and has a potential treatment for complete spinal cord injury currently in clinical phase. October 2017.

    • Initial public offering of Terveystalo Oyj (FI) on Nasdaq Helsinki — EUR 876 million

      Initial public offering of Terveystalo Oyj (FI) on Nasdaq Helsinki — EUR 876 million

      Carnegie acted as joint global co-ordinator and joint bookrunner in the initial public offering of Terveystalo on Nasdaq Helsinki. Terveystalo, majority owned by EQT, is a leading healthcare service provider in Finland offering primary and outpatient secondary healthcare services to corporate, private and public sector customers. October 2017.

    • Initial public offering of Handicare Group AB (SE) on Nasdaq Stockholm — SEK 983 million

      Initial public offering of Handicare Group AB (SE) on Nasdaq Stockholm — SEK 983 million

      Carnegie acted as joint global co-ordinator and joint bookrunner in the initial public offering of Handicare on Nasdaq Stockholm. Handicare is a leading, global provider of mobility solutions in the Accessibility and Patient Handling markets. October 2017.

    • Directed new share issue in Xbrane Biopharma AB (SE) — SEK 20 million

      Directed new share issue in Xbrane Biopharma AB (SE) — SEK 20 million

      Carnegie acted as financial adviser in the directed new share issue of 655,738 new shares at a subscription price of SEK 30.50 per share. Xbrane is a commercial phase Swedish biopharmaceutical company specialised in biosimilars and long acting injectables. June 2017.

    • Sale of a 40% minority stake in Dr. Fürst Medisinsk Laboratorium (NO) to Ferd Capital (NO) — Amount not disclosed

      Sale of a 40% minority stake in Dr. Fürst Medisinsk Laboratorium (NO) to Ferd Capital (NO) — Amount not disclosed

      Carnegie acted as financial adviser to main shareholder in Fürst in connection with the transaction. Fürst is the largest private medical laboratory in the Nordics and analyses tests from more than 10,000 patients per day. Ferd is a family-owned Norwegian investment company. June 2017.

    • Initial public offering of BONESUPPORT HOLDING AB (SE) on Nasdaq Stockholm — SEK 575 million

      Initial public offering of BONESUPPORT HOLDING AB (SE) on Nasdaq Stockholm — SEK 575 million

      Carnegie acted as joint global co-ordinator and joint bookrunner in the initial public offering of BONESUPPORT on Nasdaq Stockholm. BONESUPPORT is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bioceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs directly into the bone void. June 2017.

    • Placing of shares in GHP Specialty Care AB (SE) — SEK 111 million

      Placing of shares in GHP Specialty Care AB (SE) — SEK 111 million

      Carnegie acted as sole bookrunner in the placing of 9.2 million shares in GHP on behalf of Annedalskliniken AB, at a price of SEK 12.10 per share. GHP is a Swedish health care provider that conducts both out-patient and in-patient care in the Nordic countries and the United Arab Emirates. June 2017.

    • Initial public offering of Medicover AB (SE) on Nasdaq Stockholm — SEK 2.3 billion

      Initial public offering of Medicover AB (SE) on Nasdaq Stockholm — SEK 2.3 billion

      Carnegie acted as joint bookrunner in the initial public offering of Medicover on Nasdaq Stockholm. Medicover is a leading international healthcare and diagnostic services provider in Poland, Germany, Romania, Ukraine and certain other markets, primarily in Central and Eastern Europe. May 2017.

    • Placing of shares in Capio AB (SE) — SEK 1.3 billion

      Placing of shares in Capio AB (SE) — SEK 1.3 billion

      Carnegie acted as joint bookrunner in the placing of 26.6 million shares in Capio AB, on behalf of Nordic Capital, at a price of SEK 50.00 per share. Capio is a leading, pan-European healthcare provider offering a broad range of high quality medical, surgical and psychiatric healthcare services in four countries through its hospitals, specialist clinics and primary care units. May 2017.

    • Initial public offering of Ambea AB (SE) on Nasdaq Stockholm — SEK 2.3 billion

      Initial public offering of Ambea AB (SE) on Nasdaq Stockholm — SEK 2.3 billion

      Carnegie acted as joint global co-ordinator and joint bookrunner in the initial public offering of Ambea on Nasdaq Stockholm. Ambea offers services within disabled care, individual and family care and elderly care, with a focus on residential care and own management. March 2017.

    • Initial public offering of Oncopeptides AB (SE) on Nasdaq Stockholm — SEK 748 million

      Initial public offering of Oncopeptides AB (SE) on Nasdaq Stockholm — SEK 748 million

      Carnegie acted as joint global co-ordinator and joint bookrunner in the initial public offering of Oncopeptides on Nasdaq Stockholm. Oncopeptides is a research and development stage pharmaceutical company developing drugs for treatment of cancer. February 2017.

    • Placing of shares in Capio AB (SE) — SEK 660 million

      Placing of shares in Capio AB (SE) — SEK 660 million

      Carnegie acted as joint bookrunner in the placing of 15.2 million shares in Capio AB, on behalf of Apax Europe, at a price of SEK 43.50 per share. Capio is a leading, pan-European healthcare provider offering a broad range of high quality medical, surgical and psychiatric healthcare services in four countries through its hospitals, specialist clinics and primary care units. February 2017.

    • Directed new share issue in NEXT Biometrics Group ASA (NO) — NOK 156 million

      Directed new share issue in NEXT Biometrics Group ASA (NO) — NOK 156 million

      Carnegie acted as joint bookrunner in the directed new share issue of 1,167,000 new shares at a subscription price of NOK 134 per share. NEXT holds a unique and patented technology that enables sales of high quality sensor modules at mass market compatible price levels. February 2017.

    • Bondholder's meeting and bond tap issue in Moberg Pharma (SE) — SEK 215 million

      Bondholder's meeting and bond tap issue in Moberg Pharma (SE) — SEK 215 million

      Carnegie acted as sole adviser and joint bookrunner in bondholder's meeting with revised terms and bond tap issue in Moberg Pharma. Moberg Pharma is a profitable and growing Swedish pharmaceutical company with unique OTC product sales operations in the U.S. December 2016.

    • Private placement of shares in Moberg Pharma (SE) — SEK 148 million

      Private placement of shares in Moberg Pharma (SE) — SEK 148 million

      Carnegie acted as sole bookrunner in the private placement of shares in Moberg Pharma. Moberg Pharma is a profitable and growing Swedish pharmaceutical company with unique OTC product sales operations in the U.S. December 2016.

    • Rights issue in PledPharma (SE) — SEK 406 million

      Rights issue in PledPharma (SE) — SEK 406 million

      Carnegie acted as sole manager and financial adviser in the fully underwritten SEK 406 million rights issue in PledPharma. PledPharma is a Swedish pharmaceutical company  developing new drugs that protect the body against oxidative stress – a potentially disabling and sometimes life-threatening condition that can be caused by chemotherapy and acetaminophen poisoning. December 2016.

    • Divestment of BioPhausia AB (SE) to Karo Pharma AB (SE) by Medivir AB (SE) — Enterprice value SEK 908 million

      Divestment of BioPhausia AB (SE) to Karo Pharma AB (SE) by Medivir AB (SE) — Enterprice value SEK 908 million

      Carnegie acted as financial adviser to Medivir AB (publ) in the divestment of BioPhausia AB to Karo Pharma AB (publ). BioPhausia consists of thirteen established pharmaceutical drugs with strong brand names and long prescription traditions in the Nordics. December 2016.

    • Merger between Suomen Terveystalo Oy (FI) and Diacor Terveyspalvelut Oy (FI) — Amount not disclosed
      Merger between Suomen Terveystalo Oy (FI) and Diacor Terveyspalvelut Oy (FI) — Amount not disclosed

      Merger between Suomen Terveystalo Oy (FI) and Diacor Terveyspalvelut Oy (FI) — Amount not disclosed

      Carnegie acted as financial adviser to Terveystalo in the merger with Diacor. Diacor is a Finnish welfare company operating 13 clinics and a hospital in the Helsinki metropolitan area and one clinic in Turku. November 2016.

    • Senior secured bond issue by Alvotech HF (IS) — USD 26 million

      Senior secured bond issue by Alvotech HF (IS) — USD 26 million

      Carnegie acted as sole bookrunner in Alvotech HF’s USD 26 million senior secured bond issue. Alvotech HF is an early-stage Icelandic biopharmaceutical company that focuses purely on the biosimilar market with complete vertical integration from early R&D to commercial manufacturing. November 2016.

    • Placing of shares in Humana AB (SE) — SEK 444 million

      Placing of shares in Humana AB (SE) — SEK 444 million

      Carnegie acted as joint bookrunner in the placing of 6 million shares in Humana of behalf of Argon Capital, at a price of SEK 74 per share. Humana is a leading Nordic care company with over 14,000 full and part time employees which offers services within individual and family care, personal assistance, elderly care and housing with special service according to LSS.
      November 2016.

    • Initial public offering of Alligator Bioscience AB (SE) on Nasdaq Stockholm – SEK 483 million

      Initial public offering of Alligator Bioscience AB (SE) on Nasdaq Stockholm – SEK 483 million

      Carnegie acted as sole global co-ordinator in the initial public offering of Alligator on Nasdaq Stockholm. Alligator is a research-based biotechnology company that develops innovative immune activating antibody drugs for tumor-directed immunotherapy. November 2016.

    • Directed new share issue in Hansa Medical AB (SE) — SEK 185 million

      Directed new share issue in Hansa Medical AB (SE) — SEK 185 million

      Carnegie acted as financial adviser in the directed new share in Hansa Medical. Hansa Medical is a biopharmaceutical company focused on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection.October 2016.

    • Placing of shares in Capio AB (SE) — SEK 980 million

      Placing of shares in Capio AB (SE) — SEK 980 million

      Carnegie acted as joint bookrunner in the placing of 20 million shares in Capio AB at a price of SEK 49 per share. Capio is a leading, pan-European healthcare provider offering a broad range of high quality medical, surgical and psychiatric healthcare services in four countries through its hospitals, specialist clinics and primary care units.September 2016.

    • Cash offer for Exiqon A/S (DK) by QIAGEN N.V. (NL) — DKK 736 million

      Cash offer for Exiqon A/S (DK) by QIAGEN N.V. (NL) — DKK 736 million

      Carnegie acted as exclusive defence adviser to Exiqon A/S and its owners in the public tender offer from QIAGEN N.V. Exiqon is a market leading niche player within RNA analysis. It develops, manufactures and markets reagents and kits to test the actual contents on a molecular level of biological samples. The reagents and kits are used in biological research and development of novel medicines and molecular diagnostic tests. June 2016. 

    • Placing of shares in Attendo AB (SE) — SEK 1.9 billion

      Placing of shares in Attendo AB (SE) — SEK 1.9 billion

      Carnegie acted as joint bookrunner in the placing of 24.5 million shares in Attendo, at a subscription price at SEK 78 per share. Attendo is the leading company within care and healthcare in the Nordics.June 2016.

    • Initial public offering of Wilson Therapeutics AB AB (SE) on Nasdaq Stockholm – SEK 480 million

      Initial public offering of Wilson Therapeutics AB AB (SE) on Nasdaq Stockholm – SEK 480 million

      Carnegie acted as joint global co-ordinator and joint bookrunner in the initial public offering of Wilson Therapeutics on Nasdaq Stockholm. Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden that develops novel therapies for patients with rare diseases.May 2016.

    • Directed new share issue in NEXT Biometrics (NO) — NOK 165 million

      Directed new share issue in NEXT Biometrics (NO) — NOK 165 million

      Carnegie acted as joint bookrunner in the directed new share issue of 1.24 million new shares at a subscription price of NOK 133 per share. NEXT holds a unique and patented technology that enables sales of high quality sensor modules at mass market compatible price levels.May 2016.

    • Initial public offering of Humana AB (SE) on Nasdaq Stockholm – SEK 887 million

      Initial public offering of Humana AB (SE) on Nasdaq Stockholm – SEK 887 million

      Carnegie acted as joint global co-ordinator and joint bookrunner in the initial public offering of Humana on Nasdaq Stockholm. Humana is a leading Nordic care company with over 14,000 full and part time employees which offers services within individual and family care, personal assistance, elderly care and housing with special service according to LSS.March 2016.

    • Directed new share issue in Recipharm (SE) — SEK 276 million

      Directed new share issue in Recipharm (SE) — SEK 276 million

      Carnegie acted as sole financial adviser in the directed new share issue of 2.25 million new Class B shares at a price of SEK 122.50 per share. Recipharm provides contract manufacturing and development services for other pharmaceutical companies. Manufacturing primarily involves production of pharmaceuticals in various forms.January 2016.

    • Senior unsecured bond issue by Moberg Pharma (SE) — SEK 300 million

      Senior unsecured bond issue by Moberg Pharma (SE) — SEK 300 million

      Senior unsecured bond issue by Moberg Pharma (SE) — SEK 300 million
      Carnegie acted as joint bookrunner in Moberg Pharma SEK 300 million senior unsecured bond issue. Moberg Pharma is a profitable and growing Swedish pharmaceutical company with unique OTC product sales operations in the U.S.January 2016.

    • Acquisition of Cederroth AS (NO) by Weifa ASA (NO) — NOK 115 million

      Acquisition of Cederroth AS (NO) by Weifa ASA (NO) — NOK 115 million

      Carnegie acted as sole financial adviser to Weifa ASA in the acquisition of Cederroth AS, the company that owns the Norwegian category leading intimate care brand Asan and its Swedish counterpart Sana. Weifa is Norway's leading consumer health company. January 2016.

    • Directed new share issue in Weifa ASA (NO) — NOK 118.5 million

      Directed new share issue in Weifa ASA (NO) — NOK 118.5 million

      Carnegie acted as sole bookrunner to Weifa ASA in connection with the acquisition of Cederroth AS, and in the directed new share issue of 118.5 million new shares at a subscription price of NOK 1.00 per share. Weifa is Norway's leading consumer health company. December 2015.

    • Secondary placing of shares in Pihlajalinna (FI) — EUR 26 million

      Secondary placing of shares in Pihlajalinna (FI) — EUR 26 million

      Carnegie acted as joint lead manager in the secondary placing of 1.5 million shares in Pihlajalinna at a price of EUR 17 per share. The placing was made on behalf of Sentica. Pihlajalinna is one of the leading private social and healthcare services providers in Finland. December 2015.

    • Directed new share issue in Pihlajalinna (FI) — EUR 26 million

      Directed new share issue in Pihlajalinna (FI) — EUR 26 million

      Carnegie acted as joint lead manager in the directed new share issue of 1.5 million new shares at a subscription price of EUR 17 per share. Pihlajalinna is one of the leading private social and healthcare services providers in Finland. December 2015.

    • Initial public offering of Camurus AB (SE) on Nasdaq Stockholm — SEK 730 million

      Initial public offering of Camurus AB (SE) on Nasdaq Stockholm — SEK 730 million

      Carnegie acted as joint global co-ordinator and joint bookrunner in the initial public offering of Camurus on Nasdaq Stockholm. Camurus is a research and development based pharmaceutical company with a focus on the development and commercialisation of new and innovative pharmaceuticals for serious and chronic conditions, where there are clear medical needs and potential to significantly improve treatment. December 2015.

    • Initial public offering of Attendo AB (SE) on Nasdaq Stockholm — SEK 4.8 billion

      Initial public offering of Attendo AB (SE) on Nasdaq Stockholm — SEK 4.8 billion

      Carnegie acted as joint global co-ordinator and joint bookrunner in the initial public offering of Attendo on Nasdaq Stockholm. Attendo is the leading company within care and healthcare in the Nordics. November 2015.

    • Senior secured bond issue by Exiqon A/S (DK) — DKK 40 million

      Senior secured bond issue by Exiqon A/S (DK) — DKK 40 million

      Carnegie acted as exclusive financial adviser in Exiqon DKK 40 million senior secured bond issue. Exiqon is a market leading niche player within RNA analysis. It develops, manufactures and markets reagents and kits to test the actual contents on a molecular level of biological samples. November 2015.

    • Divestment of Growth House Holding A/S (DK) to Orifarm Generics A/S (DK) — Amount not disclosed

      Divestment of Growth House Holding A/S (DK) to Orifarm Generics A/S (DK) — Amount not disclosed

      Carnegie acted as exclusive financial adviser to the owners of Growth House Holding in the divestment to Orifarm Generics. Growth House is a highly successful developer, manufacturer and distributor of specialty and niche generic pharmaceuticals in the Nordic markets. July 2015.

    • Spin-off and listing of Vistin Pharma (NO) on Oslo Axess — NOK 171 million

      Spin-off and listing of Vistin Pharma (NO) on Oslo Axess — NOK 171 million

      Spin-off and listing of Vistin Pharma (NO) on Oslo Axess — NOK 171 millionCarnegie acted as sole financial adviser in the spin-off and listing of Vistin Pharma. Vistin Pharma is a leading producer and supplier of active pharmaceutical ingredients (API), used in medications for diabetes and pain relief, and in cough medicine, and a contract manufacturer (CMO) of finished dose tablets. June 2015.

    • Initial public offering of Capio (SE) on Nasdaq Stockholm — SEK 2.6 billion

      Initial public offering of Capio (SE) on Nasdaq Stockholm — SEK 2.6 billion

      Carnegie acted as joint bookrunner in the initial public offering of Capio on Nasdaq Stockholm. Capio is a leading, pan-European healthcare provider offering a broad range of high quality medical, surgical and psychiatric healthcare services in four countries through its hospitals, specialist clinics and primary care units. June 2015.

    • Rights issue in Hansa Medical AB (SE) — SEK 246 million

      Rights issue in Hansa Medical AB (SE) — SEK 246 million

      Carnegie acted as sole financial adviser in the fully guaranteed SEK 246 million rights issue in Hansa Medical. Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. April 2015.

    • Initial public offering of Nordic Nanovector (NO) on Oslo Stock Exchange — NOK 575 million

      Initial public offering of Nordic Nanovector (NO) on Oslo Stock Exchange — NOK 575 million

      Carnegie acted as joint book-runner in the initial public offering of Nordic Nanovector on Oslo Stock Exchange. The Company aspires to become a leading provider of Antibody-Radionuclide-Conjugate clinical solutions, to address major unmet medical needs and to advance cancer care through its innovative therapy programs and patented technologies. March 2015.

    • Redemption offer in Medivir (SE) — SEK 625 million

      Redemption offer in Medivir (SE) — SEK 625 million

      Carnegie acted as financial adviser to Medivir in respect of the redemption programme. Medivir is an emerging and profitable research based pharmaceutical company with an established marketing and sales organisation in the Nordic region with a broad portfolio of prescription pharmaceuticals. February 2015.

    • Placing of shares in Hansa Medical AB (SE) — SEK 150 million

      Placing of shares in Hansa Medical AB (SE) — SEK 150 million

      Carnegie acted as sole financial adviser in the SEK 150 million placing of Hansa Medical shares, on behalf of Farstorps Gård AB. Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. February 2015.

    • Block trade of shares in Recipharm (SE) — SEK 425 million

      Block trade of shares in Recipharm (SE) — SEK 425 million

      Carnegie acted as sole book-runner in the block trade of 2.7 million shares in Recipharm. Recipharm provides contract manufacturing and development services for other pharmaceutical companies. Manufacturing primarily involves production of pharmaceuticals in various forms. February 2015.

    • Rights issue in Oasmia Pharmaceutical AB (SE) — SEK 176 million

      Rights issue in Oasmia Pharmaceutical AB (SE) — SEK 176 million

      Carnegie acted as sole financial adviser in the rights issue of 9.8 million new shares at a subscription price of SEK 18 per share. Oasmia develops novel formulations of already established cytostatics for both human and veterinary use, which, in comparison to current alternatives, show improved performance, a reduced side-effect profile and an expanded therapeutic area.December 2014.

    • Initial public offering of Lifco (SE) on NASDAQ Stockholm – SEK 4.2 billion

      Initial public offering of Lifco (SE) on NASDAQ Stockholm – SEK 4.2 billion

      Carnegie acted as co-lead manager in the initial public offering of Lifco on NASDAQ Stockholm. Lifco’s business idea is to acquire and develop market leading, niched companies. The Company aims to secure that the subsidiaries continuously improve earnings and deliver strong cash flows.November 2014.

    • Secondary placing of shares in Recipharm (SE) — SEK 269 million

      Secondary placing of shares in Recipharm (SE) — SEK 269 million

      Carnegie acted as sole book-runner in the secondary placing of 2.3 million shares in Recipharm. The shares were sold by Carnegie on behalf of Pentafar (PT). November 2014

    • Acquisition of CDMO Lusomedicamenta Sociedade Técnica Farmacêutica S.A. (PT) by Recipharm AB (SE) — Enterprise value SEK 1 billion
      Acquisition of CDMO Lusomedicamenta Sociedade Técnica Farmacêutica S.A. (PT) by Recipharm AB (SE) — Enterprise value SEK 1 billion

      Acquisition of CDMO Lusomedicamenta Sociedade Técnica Farmacêutica S.A. (PT) by Recipharm AB (SE) — Enterprise value SEK 1 billion

      Carnegie acted as financial adviser to Recipharm in the acquisition of Lusomedicamenta. Recipharm provides contract manufacturing and development services for other pharmaceutical companies. Lusomedicamenta is primarily a CDMO specialised in the development and manufacture of solid, liquid and semi-solid dose forms as well as sterile ophthalmic products. November 2014.

    • Directed new share issue in Weifa ASA (NO) – NOK 115 million

      Directed new share issue in Weifa ASA (NO) – NOK 115 million

      Carnegie acted as joint book-runner in the directed new share issue of 144 million new shares at a subscription price of NOK 0.80 per share. Weifa ASA (formerly Aqualis ASA) has, through the recent acquisition of Weifa AS, become Norway's leading fully-integrated pharmaceutical company and a major supplier of active ingredients to the international pharmaceutical industry. September 2014. 

    • Rights issue in Weifa ASA (NO) – NOK 700 million

      Rights issue in Weifa ASA (NO) – NOK 700 million

      Carnegie acted as sole manager in the rights issue of approximately 159 million new shares at a subscription price of NOK 0.63 per share. The net proceeds shall be used to refinance existing bank loans in Weifa following the acquisition, and for general corporate purposes following Aqualis ASA’s (now Weifa ASA’s) acquisition of Weifa AS. The share issue is fully underwritten by a group of Nordic and international institutional investors and family offices, including the company's largest shareholder Ferncliff and associated companies. September 2014.

    • Acquisition of Weifa AS (NO) by Aqualis ASA (NO) — NOK 1.17 billion
      Acquisition of Weifa AS (NO) by Aqualis ASA (NO) — NOK 1.17 billion

      Acquisition of Weifa AS (NO) by Aqualis ASA (NO) — NOK 1.17 billion

      Carnegie acted as sole financial adviser to Aqualis ASA in the acquisition of Weifa AS, including the fully underwritten financing of the transaction consisting of a NOK 700 million private placement, a NOK 400 million bond issue and a NOK 100 million rights issue. Weifa is Norway’s leading fully-integrated pharmaceutical company and a major supplier of active ingredients to the international pharmaceutical industry.August 2014.

    • Merger between Falck Healthcare (DK), Quick Care (DK) and Previa (SE)  — Amount not disclosed.

      Merger between Falck Healthcare (DK), Quick Care (DK) and Previa (SE) — Amount not disclosed.

      Carnegie acted as sole financial adviser to Falck and TrygghedsGruppen in connection with the merger. The merger creates the largest healthcare service player in Scandinavia, providing a range of healthcare related and rehabilitation services to public and private companies, insurance companies and pension companies. . In addition, TryghedsGruppen becomes the owner of 2.3% of the shares in Falck Holding.July 2014.

    • Directed new share issue in Oasmia Pharmaceutical AB (SE) — SEK 50 million

      Directed new share issue in Oasmia Pharmaceutical AB (SE) — SEK 50 million

      Carnegie acted as sole manager and sole book-runner in the directed new share issue of 2.5 million new shares at a subscription price of SEK 20 per share. Oasmia develops novel formulations of already established cytostatics for both human and veterinary use, which in comparison to current alternatives show improved performance, a reduced side-effect profile and an expanded therapeutic area.July 2014.

    • Initial public offering of NEXT Biometrics Group ASA (NO) on the Oslo Axess — NOK 233 million

      Initial public offering of NEXT Biometrics Group ASA (NO) on the Oslo Axess — NOK 233 million

      Carnegie acted as joint lead manager and joint book-runner in the initial public offering of NEXT Biometrics Group on the Oslo Axess. NEXT holds a unique and patented technology that enables sales of high quality sensor modules at mass market compatible price levels.  June 2014.

    • Senior secured bond issue by Weifa ASA (formerly Aqualis ASA) (NO) – NOK 400 million

      Senior secured bond issue by Weifa ASA (formerly Aqualis ASA) (NO) – NOK 400 million

      Carnegie acted as sole manager in the NOK 400 million senior secured bond issue. The net proceeds was used to part finance the acquisition of Weifa AS, and Aqualis ASA was later renamed Weifa ASA. The bond issue was fully underwritten by a group of Nordic and international institutional investors and family offices, including the company's largest shareholder Ferncliff and associated companies. June 2014. 

    • Directed new share issue in Weifa ASA (formerly Aqualis ASA) (NO) – NOK 700 million

      Directed new share issue in Weifa ASA (formerly Aqualis ASA) (NO) – NOK 700 million

      Carnegie acted as sole manager in the directed new share issue of approximtely 1.1 billion new shares at a subscription price of NOK 0.63 per share. The net proceeds was used to part finance the acquisition of Weifa AS, and Aqualis ASA was later renamed Weifa ASA. The share issue was fully underwritten by a group of Nordic and international institutional investors and family offices, including the company's largest shareholder Ferncliff and associated companies. June 2014. 

    • Directed new share issue in Hofseth BioCare ASA (NO) — NOK 90 million

      Directed new share issue in Hofseth BioCare ASA (NO) — NOK 90 million

      Carnegie acted as joint lead manager and joint book-runner in the directed new share issue of of 20 million new shares at a subscription price at NOK 4.5 per share. Hofseth BioCare is a Norwegian biomarine company with the key objective to provide high value added biomarine ingredients for human applications. May 2014.
    • Directed new share issue in Biotec Pharmacon ASA (NO) — NOK 78 million

      Directed new share issue in Biotec Pharmacon ASA (NO) — NOK 78 million

      Carnegie acted as sole book-runner in the directed new share issue of 3.9 million new shares at a subscription price of NOK 20 per share. Biotec Pharmacon develops, manufactures and markets immune modulating compounds for the human health sectors and marine enzymes used in molecular biology. April 2014.
    • Initial public offering of Recipharm (SE) on NASDAQ OMX Stockholm — SEK 1.5 billion

      Initial public offering of Recipharm (SE) on NASDAQ OMX Stockholm — SEK 1.5 billion

      Carnegie acted as joint lead manager and joint book-runner in the initial public offering of Recipharm on NASDAQ OMX Stockholm. Recipharm provides contract manufacturing and development services for other pharmaceutical companies. Manufacturing primarily involves production of pharmaceuticals in various forms. April 2014.
    • Directed new share issue in Oasmia Pharmaceutical AB (SE) — SEK 72 million

      Directed new share issue in Oasmia Pharmaceutical AB (SE) — SEK 72 million

      Carnegie acted as adviser and sole book-runner in the directed new share issue of 3.8 million new shares at a subscription price at SEK 19 per share. Oasmia develops novel formulations of already established cytostatics for both human and veterinary use, which in comparison to current alternatives show improved performance, a reduced side-effect profile and an expanded therapeutic area. March 2014.
    • Divestment of Investor’s 14 per cent stake in Global Health Partner AB (SE)

      Divestment of Investor’s 14 per cent stake in Global Health Partner AB (SE)

      Carnegie divested 14 per cent in Global Health Partner to one domestic buyer, at a subscription price of SEK 5.35 per share. The placing was executed exclusively by Carnegie on behalf of Investor AB. May 2013.
    • Block trade of shares in Swedish Orphan Biovitrum (SE) — SEK 231 million

      Block trade of shares in Swedish Orphan Biovitrum (SE) — SEK 231 million

      Carnegie acted as sole broker in the block trade of slightly more than 6 million shares in Swedish Orphan Biovitrum, a leading European specialty pharmaceutical company. March 2013.
    • Directed new share issue in Biotec Pharmacon (NO) — NOK 40 million

      Directed new share issue in Biotec Pharmacon (NO) — NOK 40 million

      Carnegie acted as sole book-runner in the directed new share issue of 9.5 million new shares at a price of NOK 4.25 per share. Biotec Pharmacon is a biopharmaceutical company that develops and manufactures new immunomodulatory products and cold adapted marine enzymes. January 2013.
    • Rights issue in Oasmia Pharmaceutical (SE) — SEK 123 million

      Rights issue in Oasmia Pharmaceutical (SE) — SEK 123 million

      Carnegie acted as adviser to Oasmia in the rights issue of SEK 123 million. Oasmia develops novel formulations of already established cytostatics for both human and veterinary use, which in comparison to current alternatives show improved performance, a reduced side-effect profile and an expanded therapeutic area. The portfolio comprises five product candidates, of which two are in registration phase. November 2012.
    • Secondary placing of shares in William Demant Invest (DK) — DKK 1.3 billion

      Secondary placing of shares in William Demant Invest (DK) — DKK 1.3 billion

      Carnegie acted as sole broker in the secondary placing of 2.7 million shares in William Demant Holding to a few selected investors. William Demant Holding Group is a leading international health care company within Hearing Devices, Diagnostic Instruments and Personal Communication. March, 2012.
    • Directed new share issue in Clavis Pharma ASA (NO) — NOK 163 million

      Directed new share issue in Clavis Pharma ASA (NO) — NOK 163 million

      Carnegie acted as joint book-runner in the directed new share issue of 2.86 million shares at a subscription price of NOK 57.00 per share. Clavis Pharma ASA is a clinical stage oncology discovery and drug development company, with a portfolio of novel anti-cancer drugs in development. January, 2012.

    • Bond issue in Bactiguard Holding AB (SE) — SEK 450 million

      Bond issue in Bactiguard Holding AB (SE) — SEK 450 million

      Carnegie acted as sole lead manager and book-runner in Bactiguard Holding AB’s SEK 450 million bond issue. Bactiguard’s product consists of an extremely thin noble metal alloy, with antimicrobial and biocompatible properties, which is a clinically proven solution for preventing hospital and care acquired infections. December, 2011.

    • Directed new share issue in Oasmia Pharmaceutical AB (SE) — SEK 48 million

      Directed new share issue in Oasmia Pharmaceutical AB (SE) — SEK 48 million

      Carnegie acted as financial adviser in the directed new share issue of 5.2 million new shares at a price of SEK 9.30 per share. Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. October, 2011.
    • Divestment of Proxima (SE) to Aleris (SE) by CapMan (FI) — SEK 1.1 billion

      Divestment of Proxima (SE) to Aleris (SE) by CapMan (FI) — SEK 1.1 billion

      Carnegie acted as sole financial adviser to CapMan in the divestment of Proxima to Aleris. Proxima is a private healthcare company including primary care, diagnostics, specialist care, occupational care and rehabilitation. June, 2011.
    • Rights issue in Swedish Orphan Biovitrum (SE) — SEK 637 million

      Rights issue in Swedish Orphan Biovitrum (SE) — SEK 637 million

      Carnegie acted as joint lead manager and joint book-runner in the rights issue of SEK 637 million. Swedish Orphan Biovitrum is a leading European specialty pharmaceutical company. June, 2011.
    • Directed new share issue in BioInvent International (SE) — SEK 136 million

      Directed new share issue in BioInvent International (SE) — SEK 136 million

      Carnegie acted as joint global co-ordinator and joint book-runner in the directed new share issue of 6.1 million new shares at a price of SEK 22.30 per share. BioInvent International AB, listed on the NASDAQ OMX Stockholm, is a research-based pharmaceutical company that focuses on developing antibody drugs. June, 2011.
    • Rights issue in Bavarian Nordic (DK) — DKK 698 million

      Rights issue in Bavarian Nordic (DK) — DKK 698 million

      Carnegie acted as joint global co-ordinator in the rights issue of DKK 698 million. Bavarian Nordic is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. May, 2011.
    • Convertible bond issue in Bluefish Pharmaceuticals (SE) — SEK 60 million

      Convertible bond issue in Bluefish Pharmaceuticals (SE) — SEK 60 million

      Carnegie acted as sole financial adviser in Bluefish SEK 60 million convertible bond issue. Bluefish is a fast-growing Nordic generics company with a pan-European focus. May, 2011.

    • Secondary placing of 1.45 million shares in Medivir (SE) — SEK 197.2 million

      Secondary placing of 1.45 million shares in Medivir (SE) — SEK 197.2 million

      Carnegie acted as sole book-runner in the secondary placing of 1.45 million shares in Medivir, at a price of SEK 136 per share. Medivir is an emerging research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. March, 2011.
    • Directed new share issue in Active Biotech (SE) — SEK 375 million

      Directed new share issue in Active Biotech (SE) — SEK 375 million

      Carnegie acted as joint lead manager and book-runner in the directed new share issue of 2.5 million shares at a price of SEK 150 per share. Active Biotech is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. January, 2011.
    • Rights issue in Karo Bio (SE) — SEK 325 million

      Rights issue in Karo Bio (SE) — SEK 325 million

      Carnegie acted as sole lead manager in the rights issue of SEK 325 million. Karo Bio is a drug discovery and development company specialising in endocrinology and addressing nuclear receptors as target proteins for the development of novel pharmaceuticals. December, 2010.
    • Directed new share issue in Medivir AB (SE) — SEK 281 million

      Directed new share issue in Medivir AB (SE) — SEK 281 million

      Carnegie acted as joint lead manager and book-runner in the directed new share issue of 2.25 million new class B shares at a price of SEK 125 per share. Medivir is an emerging research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases December, 2010.
    • Rights issue in Oasmia Pharmaceutical (SE) — SEK 239 million

      Rights issue in Oasmia Pharmaceutical (SE) — SEK 239 million

      Carnegie acted as adviser to Oasmia in the rights issue of SEK 239 million. Oasmia Pharmaceutical AB develops second and third generation cancer drugs based on nanotechnology for human and veterinary use. The broad portfolio is focused on oncology and contains several promising products in clinical and pre-clinical phase. November, 2010.
    • Directed new share issue in Clavis Pharma ASA (NO) — NOK 154 million

      Directed new share issue in Clavis Pharma ASA (NO) — NOK 154 million

      Carnegie acted as joint lead manager and joint book-runner in the directed new share issue of 4.4 million shares at a subscription price of NOK 35.00 per share. Clavis Pharma ASA is a clinical stage oncology discovery and drug development company, with a portfolio of novel anti-cancer drugs in development. November, 2010.
    • Rights offering in Medivir (SE) — SEK 325 million

      Rights offering in Medivir (SE) — SEK 325 million

      Carnegie acted as adviser to Medivir, and underwriter, in the company's SEK 325 million rights offering. Medivir develops pharmaceuticals against major, widespread diseases, focusing on pharmaceuticals against infectious diseases caused by viruses. June, 2010
    • Divestment of Ambea (SE) by 3i (UK) and other owners to Triton (SE) — EUR 850 million

      Divestment of Ambea (SE) by 3i (UK) and other owners to Triton (SE) — EUR 850 million

      Carnegie acted as adviser to the owners in the divestment of Ambea to Triton. Ambea is the leading provider of healthcare and care services in the Nordic region and one of the largest European healthcare service providers. March, 2010.
    • Secondary placing of 1.7 million shares in Clavis Pharma ASA (NO) — NOK 84 million

      Secondary placing of 1.7 million shares in Clavis Pharma ASA (NO) — NOK 84 million

      Carnegie acted as sole manager in the secondary placing of 1.7 million shares in Clavis Pharma ASA, at a price of NOK 50.50 per share. The seller was MVM Life Science Partners LLP. Clavis Pharma ASA is an oncology focused pharmaceutical company. January, 2010.
    • Rights issue in Biovitrum (SE) — SEK 1.5 billion

      Rights issue in Biovitrum (SE) — SEK 1.5 billion

      Carnegie acted as joint lead manager and underwriter to Biovitrum in a SEK 1.5 billion rights issue, to finance the consideration paid to the shareholders in Swedish Orphan in connection with the combination of Biovitrum and Swedish Orphan. The combination will result in a the creation of a new niche specialty pharmaceutical company focused on rare diseases with pro forma revenues 2009 of approximately SEK 2 billion and an EBITDA margin of 15 percent. January, 2010.
    • Secondary placing of 5 million shares in Global Health Partner AB (SE) — SEK 53 million

      Secondary placing of 5 million shares in Global Health Partner AB (SE) — SEK 53 million

      Carnegie acted as sole manager in the secondary placing of 5 million shares in Global Health Partner, at a price of SEK 10.50 per share. The seller was Hosar International. October, 2009
    • Private placement of shares in IPC International (DK) — DDK 84 million

      Private placement of shares in IPC International (DK) — DDK 84 million

      Carnegie acted as sole financial adviser in the private placement of 184,005 shares at a subscription price of DKK 456.51 per share. IPC International A/S is a specialty pharma company primarily operating within oncology, women’s health and pain/drug abuse. The company currently markets nine specialty pharma products in the Nordic region and in the UK.  August, 2009.
    • Directed new share issue in Clavis Pharma ASA (NO) — NOK 129 million

      Directed new share issue in Clavis Pharma ASA (NO) — NOK 129 million

      Carnegie acted as joint lead manager and joint book-runner in the directed new share issue of 10.8 million shares, at a price of NOK 12.00 per share. Clavis Pharma ASA is an oncology focused pharmaceutical company. June, 2009.
    • Secondary placing of 25.3 million shares in Pronova BioPharma ASA (NO) — NOK 467 million

      Secondary placing of 25.3 million shares in Pronova BioPharma ASA (NO) — NOK 467 million

      Carnegie acted as joint book runner in the secondary placing of Pronova BioPharma. Pronova BioPharma is a global leader in the research, development and manufacture of marine-originated omega-3 derived pharmaceutical products. May, 2009.
    • Directed new share issue in Neuroserach (DK) — DKK 84 million

      Directed new share issue in Neuroserach (DK) — DKK 84 million

      Carnegie acted as joint book-runner in the directed new issue of 300.000 new shares. The new shares have been subscribed at a price of DKK 280 per share. NeuroSearch A/S is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. May, 2008.
    • Rights issue in NeuroSearch A/S (DK) — DKK 771 million

      Rights issue in NeuroSearch A/S (DK) — DKK 771 million

      Carnegie acted as joint global co-ordinator in the rights issue of 2.7 million new shares, with pre-emptive rights to existing shareholders, bringing the company gross proceeds of DKK 771 million. The subscription price was DKK 280 with a margin to TERP at launch of approx. 26 per cent. The offering was structured as a public offering in Denmark and the United Kingdom and as a private placement in other jurisdictions. NeuroSearch A/S is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. November, 2007.
    • Divestment of AB Previa (SE) to Tryg i Danmark smba (DK) by Segulah (SE) — Amount not disclosed.

      Divestment of AB Previa (SE) to Tryg i Danmark smba (DK) by Segulah (SE) — Amount not disclosed.

      Carnegie acted as adviser to Segulah in the divestment of AB Previa to Tryg Danmark smba. AB Previa is engaged in occupational health services to corporate clients as a means for improving profitability. Segulah is a private equity partnership focused on lower mid market buyouts in the Nordic region. Tryg i Danmark smba is a Danish corporation which owns and develops companies and initiatives that contribute to creating security in the Nordic region. October, 2007.
    • Initial public offering of Pronova BioPharma ASA (NO) — NOK 2.7 billion

      Initial public offering of Pronova BioPharma ASA (NO) — NOK 2.7 billion

      Carnegie acted as joint global co-ordinator and joint book-runner in the initial public offering of Pronova BioPharma ASA on the Oslo Stock Exchange. Pronova BioPharma ASA is a global leader in the research, development and manufacture of marine-originated omega-3 derived pharmaceuticals. October, 2007.
    • Secondary placing of 112,107 shares in Bavarian Nordic (DK) — DKK 69 million

      Secondary placing of 112,107 shares in Bavarian Nordic (DK) — DKK 69 million

      Carnegie acted as sole book-runner in the secondary placing of 112,107 shares in Bavarian Nordic, at a price of DKK 614.8 per share. The placing was made on behalf of a group of Bavarian Nordic employees. Buyers were solely Danish institutions. Bavarian Nordic is a leading international biopharmaceutical company developing and producing innovative vaccines to prevent and treat infectious diseases and cancer. June, 2007.
    • Secondary placing of 3 million shares in Meda (SE) — SEK 720 million

      Secondary placing of 3 million shares in Meda (SE) — SEK 720 million

      Carnegie acted as lead manager in the secondary placing of 3 million shares at a price of SEK 240 per share. Meda is one of Europe's leading specialty pharma companies. February, 2007.
    • Rights issue in Medivir (SE) — SEK 225 million

      Rights issue in Medivir (SE) — SEK 225 million

      Carnegie acted as financial adviser in the rights issue of SEK 225 million in Medivir. The new funds will be used to strengthen the capital base of Medivir, allowing the group to focus further on its prioritised projects. Medivir is an innovative, specialist research company which develops drugs with the objective of becoming a sustainably profitable pharmaceuticals company. February, 2007.
    • Secondary placing of 1.45 million shares in Orexo (SE) — SEK 175 million

      Secondary placing of 1.45 million shares in Orexo (SE) — SEK 175 million

      Carnegie acted as sole book-runner in the secondary placing of 1.45 million shares at a price of SEK 120 per share. Orexo is a product based drug delivery company which develops proprietary pharmaceuticals to address areas of unmet therapeutic need. November, 2006.
    • Initial public offering of Biovitrum (SE) — SEK 770 million

      Initial public offering of Biovitrum (SE) — SEK 770 million

      Carnegie acted as global co-ordinator and sole book-runner in the initial public offering of Biovitrum on the O-list of the Stockholm Stock Exchange. The base share offer was more than 10 times subscribed, and a total of 7,700,000 shares were sold in the offering, including the over-allotment option. The price, determined by a book-building process, was set at SEK 100 per share. Biovitrum is one of Europe’s leading biopharma companies with a broad spectrum of activities, from drug discovery, pre-clinical and clinical development to production and marketing and sales. September, 2006.
    • Public offer for Biacore International (SE) by GE Healthcare (US) — SEK 3.2 billion

      Public offer for Biacore International (SE) by GE Healthcare (US) — SEK 3.2 billion

      Carnegie acted as adviser to the Board of Biacore International in the public offer for Biacore International made by GE Healthcare. Biacore is a global supplier of systems for protein interaction analysis, an area of increasing importance for scientists in the academic, pharmaceutical, biotechnology and diagnostic markets. June, 2006.
    • New share issue and IPO in Clavis Pharma ASA (NO) — NOK 242 million

      New share issue and IPO in Clavis Pharma ASA (NO) — NOK 242 million

      Carnegie acted as lead manager in the new share issue of 4.88 million new shares at a price of NOK 45.50 per share, followed by a listing on the Oslo Stock Exchange. The new shares correspond to approximately 37 per cent of the capital of Clavis Pharma. Clavis Pharma develops new and superior pharmaceuticals based on its proprietary Lipid Vector Technology. June, 2006.
    • Acquisition of Mehiläinen (FI) by 3i (UK) and Carema Vård och Omsorg  (SE) from Praktikertjänst (SE) — EUR 152 million

      Acquisition of Mehiläinen (FI) by 3i (UK) and Carema Vård och Omsorg (SE) from Praktikertjänst (SE) — EUR 152 million

      Carnegie acted as adviser to 3i and Carema in the acquisition of Mehiläinen. Mehiläinen, founded in 1909, is a leading healthcare service provider in Finland, with a 2005 turnover of EUR 97.4 million. Mehiläinen employs 1,050 people and there are 1,800 physicians working for the company. The nationwide service network of Mehiläinen comprises 17 outpatient clinics, 7 hospitals, and occupational health care units. May, 2006.
    • Public offer for Gambro (SE) by Investor (SE) and EQT (SE) — SEK 39 billion

      Public offer for Gambro (SE) by Investor (SE) and EQT (SE) — SEK 39 billion

      Carnegie acted as financial adviser to the Board of Gambro in the public cash offer and has delivered a fairness opinion in this respect. Gambro is a global medical technology company with related services. Gambro has leading positions in renal care – services and products – and blood component technology. May, 2006.
    • Acquisition of Medihem (SE) by Carema Vård och Omsorg  (SE) and 3i (UK) from Praktikertjänst (SE) — Amount not disclosed.

      Acquisition of Medihem (SE) by Carema Vård och Omsorg (SE) and 3i (UK) from Praktikertjänst (SE) — Amount not disclosed.

      Carnegie acted as adviser to Carema and 3i in the acquisition of Medihem. Medihem is one of Sweden’s oldest private elderly care companies. Medihem has annual revenues of some SEK 400 million and approximately 600 employees. March, 2006.
    • Initial public offering of Orexo (SE) — SEK 333 million

      Initial public offering of Orexo (SE) — SEK 333 million

      Carnegie acted as joint lead manager and joint book-runner in the initial public offering of Orexo on the O-list of the Stockholm Stock Exchange. The offering, which consisted of 3.7 million newly issued shares, was fully subscribed. Orexo is a product based drug delivery company which develops proprietary pharmaceuticals to address areas of unmet therapeutic need. November, 2005.
    • Rights issue in Biotage AB (SE) — SEK 48 million

      Rights issue in Biotage AB (SE) — SEK 48 million

      Carnegie acted as sole adviser in the rights issue in Biotage AB. Slightly more than 8 million new shares have been issued, bringing to the company approximately SEK 48.3 million, excluding costs. Biotage AB is a leading supplier of complete solutions for Medicinal Chemistry Research and Applied Genetic Analysis. November, 2005.
    • New share issue in Biotage AB (SE) — SEK 97 million

      New share issue in Biotage AB (SE) — SEK 97 million

      Carnegie acted as sole manager in the directed new share issue of ten million shares in Biotage AB. Biotage AB is a leading supplier of complete solutions for Medicinal Chemistry Research and Applied Genetic Analysis. September, 2005.
    • New share issue in Biotage AB (SE) — SEK 34 million

      New share issue in Biotage AB (SE) — SEK 34 million

      Carnegie acted as sole manager in the directed new share issue of 3.4 million shares in Biotage AB. Biotage AB is a leading supplier of complete solutions for Medicinal Chemistry Research and Applied Genetic Analysis. June, 2005.
    • Secondary placing of 965,000 shares in Meda AB (SE) — SEK 300 million

      Secondary placing of 965,000 shares in Meda AB (SE) — SEK 300 million

      Carnegie acted as joint global co-ordinator and joint book-runner in the secondary placing of 965,000 shares in Meda AB to a small number of Swedish and international institutions. The placing, which was approximately 3 times covered, was priced at SEK 315 per share, equating to approximately 100 times the average daily trading volume during the last 12 months. Meda AB is a leading Nordic supplier of pharmaceuticals. May, 2005.
    • Divestment of Entific Medical Systems (SE) to Cochlear (AU) by CapMan, Investor Growth Capital and Nobel Biocare (SE) — SEK 1,050 million

      Divestment of Entific Medical Systems (SE) to Cochlear (AU) by CapMan, Investor Growth Capital and Nobel Biocare (SE) — SEK 1,050 million

      Carnegie acted as sole financial adviser to Investor Growth Capital, Capman and Nobel Biocare in the divestment of Entific Medical Systems to Cochlear, Australia. Entific develops and markets a bone anchored titanium implant system for hearing aids which is primarily used to remedy certain hearing impairments, such as conductive hearing loss and single sided deafness. March, 2005.
    • Acquisition of Attendo AB (SE) by Bridgepoint (UK) — SEK 2.2 billion

      Acquisition of Attendo AB (SE) by Bridgepoint (UK) — SEK 2.2 billion

      Carnegie acted as adviser to Bridgepoint in the the tender offer for all outstanding shares and convertible bonds in Attendo AB, a leading supplier of goods and services for elderly and disabled people. March, 2005.
    • Share buy-backs in Elekta (SE)

      Share buy-backs in Elekta (SE)

      Carnegie has purchased shares in the market on behalf of Elekta as part of Elekta's share repurchase programme. January, 2005.
    • Divestment of Swedish Orphan International AB (SE) to Investor Growth Capital (SE) and Skandia Investment (SE) — Amount not disclosed.

      Divestment of Swedish Orphan International AB (SE) to Investor Growth Capital (SE) and Skandia Investment (SE) — Amount not disclosed.

      Carnegie acted as adviser to the owners of Swedish Orphan International AB in the divestment to Investor Growth Capital and Skandia Investment. Swedish Orphan International is specialized in the development, marketing and distribution of products used for treatment of rare or life-threatening disorders, where current treatment is either unavailable or unsatisfactory. April, 2004.
    • Divestment of Pharmadule Emtunga (SE) to 3i (UK) by Industrial Development & Investment AB (
      Divestment of Pharmadule Emtunga (SE) to 3i (UK) by Industrial Development & Investment AB (

      Divestment of Pharmadule Emtunga (SE) to 3i (UK) by Industrial Development & Investment AB ("IDI") (SE) — Amount not disclosed.

      Carnegie acted as adviser to IDI in the divestment of Pharmadule Emtunga, a world leading manufacturer of high technology facilities to primarily the pharmaceutical, biotech and offshore industries. IDI is an independent private equity company focusing on small to middle-sized companies in northern Europe. 3i invests in businesses across three continents through local investment teams in Europe, Asia Pacific and the USA. February, 2004.

    • Public offer for Radiometer A/S (DK) by Danaher Corporation (US) — DKK 4.4 billion

      Public offer for Radiometer A/S (DK) by Danaher Corporation (US) — DKK 4.4 billion

      Carnegie acted as adviser to the board of directors of Radiometer in the tender offer from Danaher Corporation to acquire Radiometer. Radiometer develops and produces advanced medical instruments that measure blood gases and other parameters used to diagnose critically ill patients. January, 2004.
    • Divestment of Collet Pharma (NO) to Ferd (NO) by Nycomed (DK) — Amount not disclosed.

      Divestment of Collet Pharma (NO) to Ferd (NO) by Nycomed (DK) — Amount not disclosed.

      Carnegie acted as adviser to Nycomed in the divestment of its wholly owned Norwegian subsidiary Collet Pharma AS to Ferd. Nycomed is a European pharmaceutical company owned by CSFB Private Equity and the Blackstone Group. The company has 36 sales offices in 18 European markets. January, 2004.
    • Redemption in Elekta AB (SE) — SEK 311.5 million

      Redemption in Elekta AB (SE) — SEK 311.5 million

      Carnegie acted as adviser to Elekta in the company's share redemption programme, in which every seventeenth share could be redeemed for SEK 165 in cash. Almost 2 million shares were redeemed, equating to over 97 per cent of the shares eligible for redemption. Elekta is a world-leading supplier of advanced and innovative radiation oncology and neurosurgery solutions and services for precise treatment of cancer and brain disorders. November, 2003.
    • Acquisition of Personal Chemistry (SE) by Pyrosequencing (SE) — Amount not disclosed.
      Acquisition of Personal Chemistry (SE) by Pyrosequencing (SE) — Amount not disclosed.

      Acquisition of Personal Chemistry (SE) by Pyrosequencing (SE) — Amount not disclosed.

      Carnegie acted as adviser to Personal Chemistry in the offer from Pyrosequencing. The acquisition is intended to take place by means of a directed issue of shares and warrants in Pyrosequencing to the shareholders in Personal Chemistry. Personal Chemistry markets a new chemical analysis technology which increases and improves the chemical development work within drug discovery. October, 2003.

    • Divestment of Carmeda (SE) to HealthCap and Investor Growth Capital (SE) by Norsk Hydro (NO) — SEK 200 million
      Divestment of Carmeda (SE) to HealthCap and Investor Growth Capital (SE) by Norsk Hydro (NO) — SEK 200 million

      Divestment of Carmeda (SE) to HealthCap and Investor Growth Capital (SE) by Norsk Hydro (NO) — SEK 200 million

      Carnegie acted as financial adviser to Norsk Hydro, Norway's largest industrial group with core business areas Oil&Gas, Light Metals and Fertilizer, in the sale of Carmeda to a HealthCap and Investor Growth Capital led consortium. In addition to the cash proceeds of SEK 200 million, the sellers will receive royalties on a certain share of Carmeda's future sales revenues. Carmeda develops, produces and markets biologically active biocompatible surfaces for disposable medical devices and implants, mainly in the fields of cardiology, cardiac surgery and vascular surgery. August, 2003.

    • Divestment of Semper Clinical Nutrition business unit (SE) to Novartis (CH) by Arla Foods (SE) — Amount not disclosed.
      Divestment of Semper Clinical Nutrition business unit (SE) to Novartis (CH) by Arla Foods (SE) — Amount not disclosed.

      Divestment of Semper Clinical Nutrition business unit (SE) to Novartis (CH) by Arla Foods (SE) — Amount not disclosed.

      Carnegie acted as adviser to Arla Foods in the divestment of Semper Clinical Nutrition business unit from Arla Foods, a co-operative association owned by approximately 16,000 milk farmers in Sweden and Denmark. Novartis is a global healthcare company with leading positions within the clinical nutrition area in several markets world wide. June, 2003.

    • Rights issue in Karo Bio (SE) — SEK 125 million

      Rights issue in Karo Bio (SE) — SEK 125 million

      Carnegie acted as adviser to Karo Bio in a rights issue of approximately SEK 125 million. Karo Bio develops drugs based on nuclear receptor mechanisms. May, 2003.
    • Public offering for Pharmacia (US) by Pfizer (US) — USD 57 billion
      Public offering for Pharmacia (US) by Pfizer (US) — USD 57 billion

      Public offering for Pharmacia (US) by Pfizer (US) — USD 57 billion

      Carnegie acted as adviser to Pharmacia in Sweden in the merger with Pfizer, the largest M&A transaction announced globally in 2002. April, 2003.

    • Divestment of Maersk Medical (DK) to Nordic Capital (SE) by A.P. Møller (DK) — Amount not disclosed.
      Divestment of Maersk Medical (DK) to Nordic Capital (SE) by A.P. Møller (DK) — Amount not disclosed.

      Divestment of Maersk Medical (DK) to Nordic Capital (SE) by A.P. Møller (DK) — Amount not disclosed.

      Carnegie acted as adviser to A.P. Møller in the divestment of Maersk Medical, one of Denmark's leading med-tech companies. Maersk Medical develops, produces and markets sterile single-use medical devices to the healthcare sector. March, 2003.

    • Merger of Life Science Department of 6-AP Fund (SE) with Medicon Valley Capital (DK) and Innoventus (SE) — SEK 1.7 billion

      Merger of Life Science Department of 6-AP Fund (SE) with Medicon Valley Capital (DK) and Innoventus (SE) — SEK 1.7 billion

      Carnegie acted as adviser to 6 AP-Fund in the merger of Life Science Department of 6-AP Fund with Medicon Valley Capital and Innoventus. October, 2002.
    • Simplified procedure directed to 102,000 shareholders

      Simplified procedure directed to 102,000 shareholders

      Carnegie acted as adviser to Monsanto in the offering to small shareholders to sell or to purchase shares in Monsanto. September, 2002.
    • Pharmacia (US) / Monsanto (US) — Spin-off — USD 3.7 billion
      Pharmacia (US) / Monsanto (US) — Spin-off — USD 3.7 billion

      Pharmacia (US) / Monsanto (US) — Spin-off — USD 3.7 billion

      Carnegie acted as adviser to Pharmacia in respect of the spin-off of Pharmacia's holding in Monsanto to Pharmacia's shareholders (including 105,000 holders of Swedish depositary receipts). August, 2002.

    • Rights issue in Bavarian Nordic Research Institute A/S (DK) — DKK 50 million

      Rights issue in Bavarian Nordic Research Institute A/S (DK) — DKK 50 million

      Carnegie acted as lead manager in the rights issue in Bavarian Nordic Research Institute A/S. Bavarian Nordic Research Institute A/S is a Danish biotechnology company involved in research and development of platform technologies for the production of therapeutic vaccines and gene therapy. June, 2002.
    • Private placement in Inion Oy (FI) — EUR 16.1 million

      Private placement in Inion Oy (FI) — EUR 16.1 million

      Carnegie acted as lead manager in a private placement of EUR 16.1 million in Inion Oy, with focus on biomaterials and novel biomaterials based surgical solutions. May, 2002.
    • Secondary offering of shares in Lundbeck (DK) — DKK 1.7 billion

      Secondary offering of shares in Lundbeck (DK) — DKK 1.7 billion

      Carnegie acted as co-lead manager in the secondary offering of shares in the pharmaceuticals company Lundbeck, with a value of DKK 1.7 billion. April, 2002.
    • Private placement of equity in MariCal LLC (US) — USD 3 million

      Private placement of equity in MariCal LLC (US) — USD 3 million

      Carnegie acted as lead manager in the private placement of equity in MariCal LLC to Norwegian institutional investors with focus on life science. MariCal LLC is a US aquatic life sciences company with focus on the aquaculture industry. April, 2002.
    • Directed new share issue in Axis-Shield plc (NO and UK) — GBP 8.3 million

      Directed new share issue in Axis-Shield plc (NO and UK) — GBP 8.3 million

      Directed new share issue in Axis-Shield plc (NO and UK) — GBP 8.3 million Carnegie acted as joint lead manager in a directed new share issue of GBP 8.3 million in Axis-Shield plc towards Norwegian and UK based institutional investors. Axis-Shield, whose shares are listed on the London and the Oslo Stock Exchanges, is an international in vitro diagnostics company headquartered in Dundee with R&D and manufacturing bases in Dundee and Oslo. April, 2002.
    • Private placement of equity in UniCrop Oy (FI) — EUR 5 million

      Private placement of equity in UniCrop Oy (FI) — EUR 5 million

      Carnegie acted as lead manager in the private placement of EUR 5 million in UniCrop Oy. Unicrop Oy is a company active in research and development in plant biotechnology, and specializing in the production of therapeutic proteins in transgenic plants. March, 2002.
    • Secondary placing of shares in Capio AB (SE) — SEK 313 million

      Secondary placing of shares in Capio AB (SE) — SEK 313 million

      Carnegie placed 4,600,000 existing shares as lead manager to international and domestic institutions. Capio AB is the leading healthcare provider in Scandinavia and supplies services within some 30 medical specialist fields. December, 2001.
    • Option program in Biovitrum (SE)

      Option program in Biovitrum (SE)

      Carnegie acted as adviser to Biovitrum in the offer to all employees to purchase warrants issued by Biovitrum. Biovitrum is one of Europe's largest biotechnology companies active in the research and development of small molecule drugs and recombinant protein drugs, as well as the manufacture of recombinant protein drugs. November, 2001.
    • Divestment by Norsk Hydro ASA (NO) of Pronova Biomedical AS (NO) to FMC Corporation (US) — Amount not disclosed.

      Divestment by Norsk Hydro ASA (NO) of Pronova Biomedical AS (NO) to FMC Corporation (US) — Amount not disclosed.

      Carnegie acted as adviser to Norsk Hydro ASA in the divestment of the Pronova Biomedical AS, a leading company in developing and supplying ultrapure, well-characterized alginates and chitosans for the pharmaceutical and biomedical industry. November, 2001.
    • Private placement of equity in Boule Diagnostics (SE) — SEK 44 million

      Private placement of equity in Boule Diagnostics (SE) — SEK 44 million

      Carnegie acted as lead manager in the private placement of equity in Boule Diagnostics to institutional investors. Boule Diagnostics is working with diagnostic instruments within infection and haematology. August, 2001.
    • Divestment and equity financing of Biovitrum AB (SE) — SEK 1.6 billion
      Divestment and equity financing of Biovitrum AB (SE) — SEK 1.6 billion

      Divestment and equity financing of Biovitrum AB (SE) — SEK 1.6 billion

      Carnegie acted as adviser to Pharmacia and Biovitrum AB in the spin-off and equity financing of the biotechnology company Biovitrum AB from a division within Pharmacia to a consortium led by MPM Capital and Nordic Capital. Biovitrum AB is active in research into metabolic diseases and recombinant proteins. July, 2001.

    • Initial public offering of BioInvent International AB (SE) — SEK 372 million

      Initial public offering of BioInvent International AB (SE) — SEK 372 million

      Carnegie acted as lead manager in the initial public offering of BioInvent International AB on Stockholmsbörsen. By use of its technology platform BioInvent International AB is a partner to pharmaceutical companies within therapeutic antibodies and antibodies for use as discovery tools. June, 2001.
    • Option program in BioInvent International AB (SE)

      Option program in BioInvent International AB (SE)

      Carnegie acted as adviser to BioInvent in the offer to employees and management to purchase warrants issued by BioInvent International AB. By use of its technology platform BioInvent International AB is a partner to pharmaceutical companies within therapeutic antibodies and antibodies for use as discovery tools. June, 2001.
    • Acquisition of Accumetrics Inc. (US) by Radiometer A/S (DK) — DKK 85 million

      Acquisition of Accumetrics Inc. (US) by Radiometer A/S (DK) — DKK 85 million

      Carnegie acted as adviser to Radiometer A/S in the acquisition of Accumetrics Inc. For DKK 85 million. Radiometer A/S sells laboratory instruments. June, 2001.
    • Directed new share issue in Bavarian Nordic Research Institute A/S (DK) — DKK 80 million

      Directed new share issue in Bavarian Nordic Research Institute A/S (DK) — DKK 80 million

      Carnegie acted as lead manager in the directed new share issue in Bavarian Nordic Research Institute A/S, a Danish biotechnology company involved in research and development of platform technologies for the production of therapeutic vaccines and gene therapy. June, 2001.
    • Private placement of equity in CEBA AB (SE) — SEK 35 million

      Private placement of equity in CEBA AB (SE) — SEK 35 million

      Carnegie acted as lead manager in the private placement of equity in CEBA AB to institutional investors. CEBA AB is a company working with functional food. June, 2001.
    • Secondary placing of shares in Capio AB (SE) — SEK 1.3 billion

      Secondary placing of shares in Capio AB (SE) — SEK 1.3 billion

      Carnegie acted as co-lead manager in the secondary placement of equity in Capio AB, the leading healthcare provider in Scandinavia and supplies services within some 30 medical specialist fields. June, 2001.
    • Option program in Karo Bio (SE)

      Option program in Karo Bio (SE)

      Carnegie acted as adviser to Karo Bio in the offer to all employees to receive stock options issued by Karo Bio. Karo Bio is a drug discovery company for the development of precision drugs to treat major diseases in the field of nuclear receptors. May, 2001.
    • Option program in Q-Med AB (SE)

      Option program in Q-Med AB (SE)

      Carnegie acted as adviser to Q-Med AB in the offer to management to purchase warrants issued by Q-Med AB, a company active in pharmaceutical development within the hyaluronic acid area. May, 2001.
    • General advisory services in ProstaLund AB (SE) — SEK 100 million

      General advisory services in ProstaLund AB (SE) — SEK 100 million

      Carnegie acted as financial adviser in connection with a private placement of SEK 100 million in ProstaLund AB, a medical technology company focused on development of new products for treatment of urological conditions. April, 2001.
    • Secondary placement of shares in Karo Bio (SE) — SEK 96 million

      Secondary placement of shares in Karo Bio (SE) — SEK 96 million

      Carnegie acted as lead manager in the secondary placement of shares in Karo Bio. Karo Bio develops drugs based on nuclear receptor mechanisms. February, 2001.
    • Option program in Biacore (SE)

      Option program in Biacore (SE)

      Carnegie acted as adviser to Biacore in the offer to all employees to receive stock options issued by Biacore. The company develops, manufactures and markets advanced bioanalytical systems that provide real-time quantitative data on binding interactions between biomolecules. December, 2000.
    • Initial public offering of Capio AB (SE) — Market value approx. SEK 2.95 billion

      Initial public offering of Capio AB (SE) — Market value approx. SEK 2.95 billion

      Carnegie acted as lead manager in the initial public offering of Capio AB on Stockholmsbörsen, through a distribution of Capio AB shares to the shareholders in Bure Equity AB. Capio AB is the leading healthcare provider in Scandinavia and supplies services within some 30 medical specialist fields. October, 2000.
    • Initial public offering of Genmab A/S (DK) — DKK 1.6 billion

      Initial public offering of Genmab A/S (DK) — DKK 1.6 billion

      Carnegie acted as co-lead manager in the initial public offering of Genmab A/S on the Copenhagen Stock Exchange. Genmab A/S is a Danish biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. October, 2000.
    • Initial public offering of BioTie Therapies (FI) — EUR 21 million

      Initial public offering of BioTie Therapies (FI) — EUR 21 million

      Carnegie acted as lead manager in the initial public offering of BioTie Therapies on the Helsinki Stock Exchange. BioTie Therapies is a leading Finnish biopharmaceutical company in its core business areas, focused to develop original biopharmaceutical and pharmaceutical products in the areas of inflammation, coagulation, thrombosis and cancer. BioTie Therapies is the first biopharmaceutical company ever listed on the Helsinki Stock Exchange. June, 2000.
    • Secondary placing of shares in Q-Med AB (SE) — SEK 128 million

      Secondary placing of shares in Q-Med AB (SE) — SEK 128 million

      Carnegie placed existing shares to Nordic institutions. Q-Med AB is active in pharmaceutical development within the hyaluronic acid area. June, 2000.
    • Initial public offering of M&E Biotech A/S (DK) — DKK 375 million

      Initial public offering of M&E Biotech A/S (DK) — DKK 375 million

      Carnegie acted as lead manager in the initial public offering and the new share issue of DKK 375 million in M&E Biotech A/S on Copenhagen Stock Exchange. M&E Biotech A/S is a Danish biotechnology company focusing on therapeutic vaccines. May, 2000.
    • Initial public offering of Photocure ASA (NO) — NOK 357 million

      Initial public offering of Photocure ASA (NO) — NOK 357 million

      Carnegie acted as co-lead manager in the initial public offering and listing of Photocure ASA at the Oslo Stock Exchange. Photocure ASA is a medtech company which, inter alia, possesses a unique technology for treatment of cancer with illumination. May, 2000.
    • Directed new share issue in Karo Bio (SE) — SEK 202 million

      Directed new share issue in Karo Bio (SE) — SEK 202 million

      Carnegie acted as lead manager in a directed new share issue of SEK 202 million, allocated to Swedish and international investors. Karo Bio develops drugs based on nuclear receptor mechanisms. May, 2000.
    • Private placement of equity in Eurogene Ltd (UK/FI) — GBP 15 million

      Private placement of equity in Eurogene Ltd (UK/FI) — GBP 15 million

      Carnegie acted as co-lead manager in the private placement of GBP 15 million. Eurogene Ltd develops genetherapeutical products. April, 2000.
    • Private placement of equity in BioInvent International AB (SE) — SEK 194 million

      Private placement of equity in BioInvent International AB (SE) — SEK 194 million

      Carnegie acted as lead manager in the private placement of equity in BioInvent International AB. By use of its technology platform BioInvent International AB is a partner to pharmaceutical companies within therapeutic antibodies and antibodies for use as discovery tools. April, 2000.
    • Private placement of equity in A+ Science Investment AB (SE) — SEK 71 million

      Private placement of equity in A+ Science Investment AB (SE) — SEK 71 million

      Carnegie acted as adviser in the private placement of SEK 71 million in A+ Science Investment AB to institutional investors. A+ Science Investment AB develops pharmaceutical projects. March, 2000.
    • Vendor and cash placing for Axis-Shield (UK/NO) — NOK 342 million

      Vendor and cash placing for Axis-Shield (UK/NO) — NOK 342 million

      Carnegie acted as joint lead manager in the vendor and cash placing of NOK 342 million for Axis-Shield in connection with the acquisition of Nycomed Diagnostics. Axis-Shield develops new technologies for medical diagnostics. February, 2000.
    • Public bid and acquisition by Baxter Inc (US) of Althin Medical (SE) — SEK 1.1 billion
      Public bid and acquisition by Baxter Inc (US) of Althin Medical (SE) — SEK 1.1 billion

      Public bid and acquisition by Baxter Inc (US) of Althin Medical (SE) — SEK 1.1 billion

      Carnegie acted as adviser to Baxter Inc. in the public bid for Althin Medical, a leading manufacturer of hemodialysis products. March, 2000.

    • Acquisition by Axis-Shield (UK/NO) of Nycomed Diagnostics (NO) — NOK 288 million

      Acquisition by Axis-Shield (UK/NO) of Nycomed Diagnostics (NO) — NOK 288 million

      Carnegie acted as adviser to Axis-Shield in the acquisition of Nycomed Diagnostics in connection with a vendor and cash placing. Axis-Shield is active in development of technologies for medical diagnostics. January, 2000.
    • Licensing agreement for OXiGENE, Inc. (SE/US) — USD 70 million

      Licensing agreement for OXiGENE, Inc. (SE/US) — USD 70 million

      Carnegie acted as adviser to OXiGENE, Inc. in the negotiation and signing of a licensing and research co-operation agreement with Bristol Myers Squibb in respect of the continued development of OXiGENE, Inc.’s combretastatin technology. OXiGENE Inc. is a pharmaceutical development within cancer treatment. December, 1999.
    • Private placement of equity in A+ Science Investment AB (SE) — SEK 53 million

      Private placement of equity in A+ Science Investment AB (SE) — SEK 53 million

      Carnegie acted as sole manager in the private placement of equity in A+ Science Investment AB to institutional investors. A+ Science Investment AB is a company active in the development of pharmaceutical products. December, 1999.
    • Private placement of equity in Affitech AS (NO) — NOK 16 million

      Private placement of equity in Affitech AS (NO) — NOK 16 million

      Carnegie acted as lead manager in the private placement of equity in Affitech AS, a company active in the development of targeted antibodies for diagnostic applications. July, 1999.
    • New share issue in Axis Shield (UK/NO) — NOK 130 million

      New share issue in Axis Shield (UK/NO) — NOK 130 million

      Carnegie acted as adviser to Axis Shield in the company’s new issue of shares. Axis Shield develops technologies for medical diagnostics. July, 1999.
    • Merger of Axis Biochemicals ASA (NO) and Shield Diagnostics (UK) — NOK 970 million
      Merger of Axis Biochemicals ASA (NO) and Shield Diagnostics (UK) — NOK 970 million

      Merger of Axis Biochemicals ASA (NO) and Shield Diagnostics (UK) — NOK 970 million

      Carnegie acted as adviser to Axis Biochemicals ASA in the merger with Scottish diagnostic company Shield Diagnostics. The combined entity is a significant in-vitro diagnostics company listed in Oslo and London. June, 1999.

    • Private placement of equity in Photocure ASA (NO) — NOK 117 million

      Private placement of equity in Photocure ASA (NO) — NOK 117 million

      Carnegie acted as lead manager in the private placement of equity in Photocure ASA, a medtech company which, inter alia, possesses a unique technology for treatment of cancer with illumination. May, 1999.
    • Private placement of equity in M&E Biotech A/S (DK) — DKK 32 million

      Private placement of equity in M&E Biotech A/S (DK) — DKK 32 million

      Carnegie acted as lead manager in the private placement of equity in M&E Biotech A/S, a Danish biotechnology company focusing on therapeutic vaccines. May, 1999.
    • Private placement of equity in FibroGen Europe Oy (FI) — FIM 57 million

      Private placement of equity in FibroGen Europe Oy (FI) — FIM 57 million

      Carnegie acted as sole manager in the private placement of equity in the European subsidiary, FibroGen Europe Oy, a company active within the field of medical devices and biomaterial development from recombinant collagen and gelatine. April, 1999.
    • Private placement of equity in Carmel Pharma AB (SE) — SEK 20 million

      Private placement of equity in Carmel Pharma AB (SE) — SEK 20 million

      Carnegie acted as lead manager in the private placement of equity in Carmel Pharma AB, a company involved in the development of a medical device for eliminating exposure and contamination by cytostatic and antiviral drugs. January, 1999.
    • Directed new share issue in Axis Biochemicals ASA (NO) — NOK 31 million

      Directed new share issue in Axis Biochemicals ASA (NO) — NOK 31 million

      Carnegie acted as sole manager to Axis Biochemicals ASA in the company’s directed new issue. Axis Biochemicals ASA is listed on the Oslo Stock Exchange and develops technologies for medical diagnostics. November, 1998.
    • Initial public offering of Bavarian Nordic Research Institute A/S (DK) — DKK 195 million

      Initial public offering of Bavarian Nordic Research Institute A/S (DK) — DKK 195 million

      Carnegie acted as global co-ordinator in the new share issue and the initial public offering of Bavarian Nordic Research Institute A/S on the Copenhagen Stock Exchange. Bavarian Nordic Research Institute A/S is a Danish biotechnology company involved in research and development of platform technologies for the production of therapeutic vaccines and gene therapy. November, 1998.

    • Convertible rights issue in Elekta (SE) — SEK 467 million

      Convertible rights issue in Elekta (SE) — SEK 467 million

      Carnegie acted as lead manager in Elekta's convertible rights issue. Elekta is active within medical technology, development of the Leksell Gamma Knife and products within neurosurgery. July, 1998.
    • Private placement of equity in Phytera Inc. (US) — USD 7.6 million

      Private placement of equity in Phytera Inc. (US) — USD 7.6 million

      Carnegie acted as sole manager in the private placement of equity in Phytera Inc., active within pharmaceutical development from plant and marine microorganism cultures. July, 1998.
    • Directed issue of shares in Active Biotech (SE) — SEK 340 million

      Directed issue of shares in Active Biotech (SE) — SEK 340 million

      Carnegie acted as adviser to Active Biotech in connection with the directed issue of SEK 340 million to institutional investors. Active Biotech is a biotechnology company focusing on development and distribution of vaccines and research in inflammatory diseases. June, 1998.
    • Acquisition of Lund Research Center (SE) by Active Biotech AB (SE) from Pharmacia & Upjohn (US) — SEK 380 million

      Acquisition of Lund Research Center (SE) by Active Biotech AB (SE) from Pharmacia & Upjohn (US) — SEK 380 million

      Carnegie acted as adviser to Active Biotech AB in the acquisition of Lund Research Center through a directed issue of 2 million shares to Pharmacia & Upjohn. Active Biotech AB is a Swedish biotechnology company focusing on development and distribution of vaccines and research in inflammatory diseases. May, 1998.
    • Directed share issue in MiniDoc AB (SE) — SEK 25 million

      Directed share issue in MiniDoc AB (SE) — SEK 25 million

      Carnegie acted as adviser to MiniDoc AB in the directed share issue of SEK 25 million. MiniDoc AB is active in computer support to clinical trials. May, 1998.
    • Rights issue in Active Biotech (SE) — SEK 255 million

      Rights issue in Active Biotech (SE) — SEK 255 million

      Carnegie acted as lead manager in a rights issue of shares in Active Biotech, a Swedish biotechnology company focusing on development and distribution of vaccines and research in inflammatory diseases. May, 1998.
    • Secondary offering of shares in NeuroSearch A/S (DK) — DKK 275 million

      Secondary offering of shares in NeuroSearch A/S (DK) — DKK 275 million

      Carnegie acted as lead manager in the secondary offering of shares in NeuroSearch A/S, active in pharmaceutical development within the CNS-area. March, 1998.
    • Private placement of equity in Biofield Corp. (US) — SEK 72 million

      Private placement of equity in Biofield Corp. (US) — SEK 72 million

      Carnegie acted as Nordic lead manager in the private placement of SEK 72 million in Biofield Corp. from European and US investors. Biofield Corp. is a US company focusing on non-invasive diagnostic technique in breast cancer. December, 1997.
    • Private placement of equity in Colifast Systems ASA (NO) — NOK 32 million

      Private placement of equity in Colifast Systems ASA (NO) — NOK 32 million

      Carnegie acted as joint lead manager in a private placement of NOK 32 million in Colifast Systems ASA to institutional and private investors in Norway. Colifast Systems ASA is a Norwegian company focusing on developing products for bacterial diagnostics. October, 1997.
    • New share issue in MiniDoc AB (SE) — SEK 48 million

      New share issue in MiniDoc AB (SE) — SEK 48 million

      Carnegie acted as adviser to MiniDoc AB in the new share issue to European investors. MiniDoc AB is active in computer support to clinical trials. June, 1997.
    • Private placement of equity in M&E Biotech A/S (DK) — DKK 80 million

      Private placement of equity in M&E Biotech A/S (DK) — DKK 80 million

      Carnegie acted as lead manager in a private placement of equity in M&E Biotech A/S primarily to institutional investors in Denmark and Sweden. M&E Biotech A/S is a Danish biotechnology company focusing on therapeutic vaccines. June, 1997.
    • Divestment of SBL Vaccin (SE) by the Swedish Government (SE) — SEK 345 million
      Divestment of SBL Vaccin (SE) by the Swedish Government (SE) — SEK 345 million

      Divestment of SBL Vaccin (SE) by the Swedish Government (SE) — SEK 345 million

      Carnegie acted as adviser to the Swedish Government in the divestment of vaccine distributor SBL Vaccin to Active Biotech, a health care investment company. For SEK 145 million and a new share issue of SEK 200 million the divestment process was a limited controlled auction aimed at US and European trade buyers and investment groups. June, 1997.

    • Private placing of equity in Q-Med AB (SE) — SEK 26 million

      Private placing of equity in Q-Med AB (SE) — SEK 26 million

      Carnegie acted as sole manager in the private placement of equity in Q-Med AB to Swedish investors. Q-Med AB is active in pharmaceutical development within the hyaluronic acid area. May, 1997.
    • Acquisition and new share issue in Elekta AB (SE) — Amount not disclosed.

      Acquisition and new share issue in Elekta AB (SE) — Amount not disclosed.

      Carnegie acted as adviser to Elekta in the acquisition of the Radiation Therapy Division of Philips Medical Systems. Carnegie also acted as adviser in the new share issue of SEK 326 million to European and US investors. Elekta AB is a medical technology company involved in development, production and sales of products within neurosurgery. March, 1997.
    • Initial public offering and new share issue in Biora AB (SE) — SEK 449 million

      Initial public offering and new share issue in Biora AB (SE) — SEK 449 million

      Carnegie acted as Nordic lead manager in the new share issue and initial public offering on Nasdaq (US) and Stockholmsbörsen. Biora AB develops products for the treatment of periodontal disease and for use in oral surgery. February, 1997.
    • Secondary offering and initial public offering of OXiGENE Inc. (US) — USD 29 million

      Secondary offering and initial public offering of OXiGENE Inc. (US) — USD 29 million

      Carnegie acted as adviser to OXiGENE Inc. in the secondary offering of shares to European investors and in the initial public offering on Stockholmsbörsen. OXiGENE Inc. is active in pharmaceutical development within cancer treatment, and publicly traded at Nasdaq (US). November, 1996.
    • Private placement of equity in Phytera Inc. (US) — USD 12.3 million

      Private placement of equity in Phytera Inc. (US) — USD 12.3 million

      Carnegie acted as sole manager in the private placement of equity in Phytera Inc. to Scandinavian investors. Phytera Inc. is active within pharmaceutical development from plant and marine microorganism cultures. November, 1996.
    • SBI-listing and new share issue in MiniDoc AB (SE) — SEK 58 million

      SBI-listing and new share issue in MiniDoc AB (SE) — SEK 58 million

      Carnegie acted as adviser to MiniDoc AB in the new share issue to European investors. Unofficial listing on the SBI-list, Stockholm. MiniDoc AB is active in computer support to clinical trials. July, 1996.
    • New share issue in Axis Biochemicals ASA (NO) — NOK 72 million

      New share issue in Axis Biochemicals ASA (NO) — NOK 72 million

      Carnegie acted as adviser to Axis Biochemicals ASA in the new share issue of NOK 72 million. Axis Biochemicals ASA is active within development of technologies for medical diagnostics. July, 1996.
    • Initial public offering and new share issue in NeuroSearch A/S (DK) — DKK 280 million

      Initial public offering and new share issue in NeuroSearch A/S (DK) — DKK 280 million

      Carnegie acted as adviser to NeuroSearch A/S in the initial public offering and new share issue of DKK 280 million to Nordic and international investors. NeuroSearch A/S is active in pharmaceutical development within the CNS-area. June, 1996.
    • SBI-listing and new share issues in OXIGENE Inc. (US/SE) — Amount not disclosed.

      SBI-listing and new share issues in OXIGENE Inc. (US/SE) — Amount not disclosed.

      Carnegie acted as adviser to OXiGENE Inc. in the publicly traded at Nasdaq (US), and in the secondary offering of USD 10 million to Swedish investors. OXiGENE Inc. was unofficial listing on the SBI list, Stockholm. OXiGENE Inc. is a pharmaceutical development within cancer treatment. July, 1995.
    • Initial public offering and secondary offering of shares in Meda AB (SE) — SEK 155 million

      Initial public offering and secondary offering of shares in Meda AB (SE) — SEK 155 million

      Carnegie acted as adviser to Meda AB in the initial public offering of Meda AB on Stockholmsbörsen. In connection with the initial public offering, a secondary offering of SEK 155 million was offered to Swedish investors. Meda AB is a leading Nordic supplier of pharmaceuticals. June, 1995.
    • Private placement of equity in NeuroSearch A/S (DK) — DKK 38 million

      Private placement of equity in NeuroSearch A/S (DK) — DKK 38 million

      Carnegie acted as sole manager to NeuroSearch A/S in the private placement of DKK 38 million. NeuroSearch A/S is active in pharmaceutical development within the CNS-area. June, 1995.
    • Private placement of equity in NeuroSearch A/S (DK) — DKK 31 million

      Private placement of equity in NeuroSearch A/S (DK) — DKK 31 million

      Carnegie acted as sole manager to NeuroSearch A/S in the private placement of DKK 31 million. NeuroSearch A/S is active in pharmaceutical development within the CNS-area. July, 1994.

    • Initial public offering of Elekta (SE) — SEK 200 million

      Initial public offering of Elekta (SE) — SEK 200 million

      Carnegie acted as lead manager in the initial public offering of Elekta on Stockholmsbörsen. In connection with the initial public offering, a new share issue of SEK 200 million was offered. Elekta is a a medical technology company involved in development, production and sales of products within neurosurgery. March, 1994.
    • New share issue in Elekta (SE) — SEK 200 million

      New share issue in Elekta (SE) — SEK 200 million

      Carnegie acted as lead manager in the new share issue of SEK 200 million in Elekta. The new share issue was in connection with the initial public offering. Elekta is a a medical technology company involved in development, production and sales of products within neurosurgery. March, 1994.
© Copyright Carnegie Investment Bank AB 2018. Alla rättigheter är reserverade.